Evidence map›Paper›PMID 30354027›Full record

ArticleMolecular nutrition & food research2018

Identification of a TLR2 Inhibiting Wheat Hydrolysate.

Mensiena B G Kiewiet, Renske Dekkers, Martine P van Gool, Laurien H Ulfman, Andre Groeneveld, Marijke M Faas, Pau de Vos

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular nutrition & food research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Identification of a TLR2 Inhibiting Wheat Hydrolysate.Molecular nutrition & food research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mensiena B G KiewietImmunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700, RB, Groningen, The Netherlands.
Renske DekkersFrieslandCampina, Stationsplein 4, 3818, LE, Amersfoort, The Netherlands.
Martine P van GoolFrieslandCampina, Stationsplein 4, 3818, LE, Amersfoort, The Netherlands.
Laurien H UlfmanFrieslandCampina, Stationsplein 4, 3818, LE, Amersfoort, The Netherlands.
Andre GroeneveldFrieslandCampina, Stationsplein 4, 3818, LE, Amersfoort, The Netherlands.
Marijke M FaasImmunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700, RB, Groningen, The Netherlands.
Pau de VosImmunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700, RB, Groningen, The Netherlands.
FrieslandCampina (Netherlands) · NLUniversity of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

scopeWheat hydrolysates are used in medical nutrition to provide undernourished patients a readily digestible protein source, for instance to recover from chemotherapy-induced intestinal mucosal inflammation. Since many hydrolysates of different sources can modulate the immune system, likely via Toll-like receptors (TLRs), it is hypothesized that also wheat hydrolysates might interact with TLR signaling, which could be a way to prevent intestinal inflammation and damage. METHODS AND

resultsThe capacity of three wheat hydrolysates to modulate immunity by interfering with TLR signaling is determined. All wheat hydrolysates have TLR modulating effects but only one has strong TLR2 inhibiting effects, attenuating both TLR2/1 and TLR2/6 signaling in a reporter cell system. This is likely induced by direct TLR2-ectodomain binding, as confirmed by ELISA. Furthermore, this TLR2 blocking hydrolysate reduces IL-6 production in human dendritic cells. Application of reversed-phase-ultra HPLC combined with MS reveals that the presence of peptide WQIPEQSR is associated with the observed TLR2 inhibiting capacity.

conclusionThe study demonstrates TLR2-inhibiting capacities of a wheat hydrolysate. The findings provide a good start for further research to investigate whether this hydrolysate might contribute to the management of intestinal mucosal inflammation in cancer patients receiving chemotherapy.

Indexed as

CytokinesDendritic CellsDose-Response Relationship, DrugHumansHydrolysisInterleukin-6PeptidesProtein DomainsSignal TransductionToll-Like Receptor 1Toll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 6Toll-Like Receptor 9TriticumCytokinesIL6 protein, humanInterleukin-6PeptidesTLR1 protein, humanTLR2 protein, humanTLR4 protein, humanTLR6 protein, humanTLR9 protein, humanToll-Like Receptor 1Toll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 6Toll-Like Receptor 9bioactive peptidesinhibitionmucositistoll-like receptor 2wheat hydrolysates

Identifiers

PMID30354027
PMCPMC6646915
OpenAlexW2898521109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.